CNS

Donanemab (Kisunla)

Eli Lilly

Anti-amyloid antibody targeting plaque-specific pyroglutamate form. FDA approved July 2024. Post-marketing studies and prevention trials ongoing. Note: shares AHEAD NCT with lecanemab — Lilly-sponsored Phase 4 studies tracked separately.

Alzheimer's DiseaseEarly AD

Linked Studies

NCT04468659PrimaryACTIVE_NOT_RECRUITINGPHASE3

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

Preclinical Alzheimer's DiseaseEarly Preclinical Alzheimer's DiseaseUpdated Mar 2026

Loading comments…

Also Known As

Other names

donanemab

Search all trials →Request coverage update